Prostate Cancer Treatment in India — Advanced, Precise, Affordable
Prostate cancer is among the most common cancers in men from the Gulf region, and India offers Da Vinci robotic-assisted radical prostatectomy, High-Intensity Focused Ultrasound (HIFU), brachytherapy, stereotactic body radiation therapy (SBRT), and androgen deprivation therapy. Robotic prostatectomy achieves precision cancer removal, minimal blood loss, nerve-sparing technique to preserve continence and sexual function, with just a 2–3 day hospital stay. HIFU is a completely non-invasive option using high-frequency ultrasound waves to destroy cancer cells without surgery — ideal for localised prostate cancer with minimal side effects.
Why India? Key Points
- Robotic prostatectomy $6,000–$9,000 in India vs $25,000–$40,000 in the USA
- HIFU non-invasive treatment available at select hospitals
- Da Vinci robotic nerve-sparing prostatectomy — preserves continence
- PSA testing and MRI-guided biopsy for accurate staging
- Hormone therapy (ADT) drugs at 60–70% lower cost
- Urological oncologists with 500+ robotic prostatectomies performed
Procedures Covered
- Robotic Radical Prostatectomy (Da Vinci)
- HIFU (High-Intensity Focused Ultrasound)
- Radiation Therapy (IMRT/SBRT)
- Brachytherapy (Seed Implants)
- Androgen Deprivation Therapy (ADT)
- Chemotherapy for Advanced Prostate Cancer
🏥 Best Hospitals for Prostate Cancer Treatment in India
👨⚕️ Top Cancer Treatment Doctors in India
Frequently Asked Questions
Robotic prostatectomy: $6,000–$9,000. HIFU: $5,000–$8,000. IMRT radiation: $5,000– $10,000. Hormone therapy/month: $200–$500. All 65–80% less than Gulf.
Yes. Da Vinci robotic system available. Surgeons with 1,000+ robotic prostatectomies. Nerve-sparing technique preserves urinary function.
Non-invasive ultrasound treatment that destroys cancer cells without surgery. Ideal for localised prostate cancer. Most patients go home same day.
Robotic prostatectomy: 7–10 days. HIFU: 3–5 days. SBRT radiation: 2 weeks. Hormone injections continued at home.
Yes. Active surveillance is an option for very low-risk early prostate cancer. Oncologists will assess suitability.